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Introduction
Lysosomal storage diseases develop when cells are missing one of the many lysosomal enzymes essential for breaking down natural macromolecules. Typically, the undegraded molecules accumulate in the lysosomes to form storage granules, which eventually distort cellular structure and compromise function. The result is a chronic and progressive condition that causes a variety of physiological problems often leading to organ failure and premature death. Mucopolysaccharidosis (MPS) type VII, or Sly syndrome, is a lysosomal storage disease that develops when there is insufficient ␤-glucuronidase (GUS) to aid in the breakdown of glycosaminoglycans (GAGs) . 1 This disease is characterized by mental retardation, abnormal bone development, distorted features, and organ malfunctions leading eventually to organ failure. 2 Fortunately, Sly syndrome is rare; however, because a great deal is known about GUS and because there are animal models of this disease, Sly syndrome has become a paradigm for the study of lysosomal storage diseases in general and for gene therapy in particular.
Both dog 3 and mouse 4 models of MPS VII have been studied. In these models animals homozygous for mutations eliminating GUS activity display symptoms analogous to those in humans with Sly syndrome. In mice, the mutation is a spontaneous, single base pair deletion that results in a frameshift and a subsequent stop codon in the sequence coding for the GUS protein. 5 Without GUS activity GAGs cannot be completely catabolized and therefore accumulate in the lysosomes to form stor-age granules or vacuoles in almost all tissues. This in turn results in animals that have distorted facial features, defects in skeletal development, dwarfism, reduced learning capacity, and early death at approximately 5 months of age. 4, 6 Another useful mutation in mice is the 'nearly null' GUS mutation, which was developed by V Chapman at Roswell Park Cancer Institute. These mice have only 1-3% of normal GUS activity yet do not display any overt MPS phenotypes. This implies that if a therapy provided even a minimal amount of GUS activity, the progression of MPS pathology would be halted or reversed.
Using the mouse model for MPS VII, several experimental therapies have been tried. These include enzyme replacement, 7, 8 a variety of cell transplantation approaches, 6, [9] [10] [11] [12] [13] [14] and direct administration of adenoviral vectors. 15, 16 All of these treatments provided measurable improvement, but none was entirely satisfactory. Major problems that need to be overcome are the transient nature of enzyme replacement and adenoviral vector therapies, the invasiveness and potential complications of transplantation therapies, and the difficulty in restoring therapeutic GUS activity throughout the organism. The brain in particular has resisted most forms of therapy. 14, 17 Adeno-associated virus (AAV) provides another potential vector for the delivery of GUS genes to mutant cells. In a number of pilot studies the lacZ gene delivered by an AAV vector has been shown to make active ␤-galactosidase in cultured cells and animal tissues. [18] [19] [20] [21] In treated muscle of immunocompetent mice, this expression was shown to persist for 1.5 years. 19 Potentially therapeutic proteins that have been shown to be delivered and expressed by AAV vectors include erythropoietin, 20 cystic fibrosis transmembrane conductance regulator, 22 blood coagulation factor IX, 23, 24 and GUS. 21 In none of these cases, however, were experiments designed to show that the AAV-mediated gene therapy actually affected the long-term course of a disease. Results presented here show that MPS VII mice treated with an AAV vector containing mouse GUS cDNA (AAV-GUS) acquire the ability to make GUS enzyme for an extended period of time. Furthermore, this approach has a beneficial effect on the disease as it reduces or eliminates GAG storage in at least some tissues. To our knowledge, this is one of the first examples of an AAV vector providing successful replacement gene therapy for a naturally occurring genetic disease.
Results
Animal models MPS mice display disease symptoms and are homozygous for the mutant allele, mps, of the ␤-glucuronidase gene, Gus. 4 Nearly null or NN mice have the genotype Gus am/am and do not display storage disease symptoms in spite of their low levels of GUS enzyme. A comparison of GUS activities among normal (Gus
), MPS and NN mice is shown in Table 1 . These data suggest that 1-3% of normal GUS activity is sufficient to prevent the accumulation of undegraded GAGs and the resultant disease symptoms. Interestingly, the low, but measurable, GUS activities in MPS mice do not show the same tissuespecific distribution as GUS in normal and NN mice.
AAV vector
To deliver the GUS coding sequence as an agent of therapy, an AAV-GUS vector was created in which the rep and cap genes of the native virus were removed and replaced by a GUS cDNA driven by a CMV promoter. The only AAV viral sequences that remained were the short inverted terminal repeats (ITRs) at either end. These were essential for packaging the vector construct in AAV capsid.
To test the ability of AAV-GUS to produce GUS enzyme, cultured B lymphocytes derived from a human MPS patient were exposed to the vector particles. (The immortalized lymphocyte cell line was provided by I Olsen, Eastman Dental Institute, University College London.) GUS activity produced was dependent on the dose of AAV-GUS (Table 2) , although the multiplicities of infection (based on the physical titer) were high. GUS expression diminished with continued culture suggesting that the majority of transcribed vector was not integrated into the cell genome, but rather was diluted out as cells divided.
Intramuscular administration of AAV-GUS
Two MPS animals were injected with a high dose of AAV-GUS in the hind limb muscles (2.5 × 10 12 particles per limb) and GUS activity in several tissues was measured 2 weeks later (Table 3) . GUS expression in injected muscle was exceptionally high while GUS levels in all other tissues tested were low. Lower doses of AAV-GUS (3.4 × 10 11 particles per limb) yielded similar, tissuespecific patterns 17 weeks after administration; that is, high expression of GUS was confined exclusively to the injected limbs, which had a mean specific activity of 86 ± 12 U/g (n = 6).
Because the response to AAV-GUS was high in muscles, we could use NN mice rather than MPS mice for additional experiments. The advantage of using NN mice was that they could be bred as homozygotes (unlike MPS mice) and therefore provided more experimental subjects per breeding cage. Also, the overall health of NN mice did not deteriorate at an accelerated pace, as was the case for MPS mice. To look at the dose-response, NN 12 particles per limb. Mice were 1-2 months old at the time of injection and GUS enzyme activity (Units/g tissue) was assayed 2 weeks after injection. Data are the average of two treated mice. mice were injected as indicated in Table 4 . After 2 weeks mice were killed, muscles were dissected from the hind limbs, and GUS enzyme activity was assayed. GUS activity increased with AAV-GUS dose to levels far in excess of normal enzyme levels.
To determine the time-course of AAV-GUS expression, NN mice were injected in the hind limbs using 3.4 × 10 11 particles AAV-GUS per limb. Three injected NN mice were killed at each time-point. Right and left legs including muscle and bone but not skin, were recovered, homogenized separately, and then assayed for GUS activity. The mean GUS activity levels of injected limbs for each time-point are shown in Figure 1a . The background level of enzyme activity at 0 days for untreated NN mice was 0.085 U/g tissue. GUS activity at 11 weeks after treatment was more than 200 times the activity in the leg of a normal, non-mutant animal. A single mouse from this
Figure 1 Time course of (a) GUS expression and (b) vector DNA concentration following intramuscular administration of AAV-GUS to NN mice. Each time-point (with bars) represents the mean (±s.e.) of six samples comprised of right and left hind limbs from three animals. AAV-GUS concentration is relative to total (genomic) DNA.
experiment was assayed 26 weeks after AAV-GUS administration and had 108 U/g in one leg and 57 U/g in the other, suggesting that high expression continued for an extended time.
Homogenates used for the time-course shown in Figure 1a were also used to extract DNA and measure AAV-GUS by quantitative PCR. The mean concentration of vector DNA for each point of the time-course is shown in Figure 1b . One day after injection, the concentration of vector DNA was 8.5 ng/g total DNA. After declining rapidly at first, it eventually approached an asymptotic level (7 pg/g total DNA) that represented about 0.1% of the starting vector DNA. A similar experiment using a lower dose of AAV-GUS confirmed the initial rapid loss of AAV-GUS DNA; compared with the amount of vector DNA 30 min after administration, 34, 16 and 13% remained after 1, 2 and 3 days.
Intravenous administration of AAV-GUS to MPS mice MPS mice 4-6 weeks old were injected via the tail vein with AAV-GUS suspended in saline. Results are shown in Table 5 . Compared with intramuscular injection, intravenous injection resulted in a broader tissue distribution of GUS activity. However, of the tested tissues only the liver, heart and muscles had substantially more GUS activity than untreated mutants. This pattern was seen in all animals tested; however, the extent of GUS expression in a given tissue at a given time-point could vary considerably from animal to animal (note SE). This was particularly true for muscle, a tissue that has low normal levels of GUS and in which the vector was expressed with relatively high efficiency (see Discussion). Thus, although GUS levels in muscle following intravenous administration were always elevated, the apparent spike in muscle GUS activity seen after 8 weeks of treatment is probably not reproducible. The livers of three animals treated for 13 weeks were also tested for the presence of vector DNA by quantitative PCR. AAV-GUS was present at a concentration of 12 ± 3 pg/g of total DNA. Other tissues were not tested for the presence of AAV-GUS DNA.
Expression levels of GUS were modest following intravenous injection. To see if there was sufficient enzyme to reduce the stored GAG levels, mice were treated intravenously with 10 12 particles of AAV-GUS and GAG levels were measured after 3 or 8 weeks. The results showed that GAG levels in the liver returned to normal after treatment with vector ( Table 6) .
One of the most dramatic characteristics of MPS disease is the appearance of large, cytoplasmic, storage vacuoles apparent by microscopic examination of tissue sections. 25 MPS mice injected intravenously with either 10 12 AAV-GUS particles or saline alone were killed 4 weeks after administration and examined histologically. Liver sections from control MPS mice showed moderate to severe, diffuse, cytoplasmic vacuolations in hepatocytes and sinusoidal reticulo-endothelial cells (Figure 2b) . Livers from treated mice had a substantial reduction of storage vacuoles resulting in normal tissue architecture (Figure 2c and d) . This was true for each of three treated MPS mice. Two saline treated and three untreated MPS mice all had extensive storage while normal (Figure 2a ) and NN mice (not shown) did not. Liver sections from MPS mice killed 13 weeks after AAV-GUS administration were indistinguishable from normal. MPS mouse kidney Mice were injected via the tail vein with 10 12 AAV-GUS particles in 200 l saline. After each time-period n mice were killed and GUS activity was assayed. Enzyme data are means ± s.e. and brain, both low in GUS activity in these experiments, retained storage granules in spite of treatment.
Immune response
Although most laboratories that have attempted gene therapy in MPS mice have used a human GUS cDNA clone, we used a mouse cDNA clone in order to reduce the risk of eliciting an immune response against the therapeutic protein. To see if immunity still developed, we collected serum from MPS animals treated either intravenously or intramuscularly with AAV-GUS and tested for antibody against partially purified mouse GUS using a Staphylococcus aureus (protein A) method to sediment antigen/antibody complexes. 26 No anti-GUS antibody was detected. We also showed that low GUS levels in MPS mice are due to GUS protein and not some other enzyme with limited cross-substrate activity; goat antibody against highly purified mouse GUS completely eliminated the residual GUS activity in untreated MPS mice.
To determine if mice treated with AAV-GUS develop immunity against the encapsidated vector, NN mice were injected in the right hind limb with vector and 6 weeks later were given a comparable injection in the left hind limb. The first treatment with vector eliminated a response to the second administration (data not shown).
Discussion
Results presented show that administration of AAV-GUS vector can produce GUS enzyme for extended periods of time. In general, intramuscular administration resulted in high levels of GUS localized to the injection area, whereas intravenous injection provided much lower, but more widely spread GUS activity. By comparison, intraperitoneal administration of AAV-GUS was ineffective except in abdominal muscle at the site of injection (data not shown).
Although AAV-GUS administered to skeletal muscle produced GUS at levels far in excess of normal, no negative side-effects were observed (eg decreased weight, decreased mobility, increased mortality). At the other end of the spectrum, untreated NN mice show that modest levels of GUS are sufficient to prevent disease characteristics. This implies that a broad range of GUS activities, from a few percent to many times normal, would be acceptable in providing effective therapy.
With the high production of GUS in muscle, one might expect some redistribution of activity to other tissues. Enzyme replacement studies showed that virtually all cell types are able to take up GUS enzyme from the circulatory system, presumably via the mannose-6-phosphate receptor. 7 Furthermore, implanted organoids containing GUS-positive cells, and genetically modified myoblasts engrafted into muscle have been shown to secrete GUS enzyme that is subsequently taken up by cells in other organs. 11, 12, 27 However, even though intramuscular administration of AAV-GUS resulted in far more than enough GUS to cure the whole mouse, no activity was detected in circulation and little activity above mutant basal levels was detected in any other tissue. One possibility is that GUS made from injected vector is not properly glycosylated and phosphorylated for recognition by the mannose-6-phosphate receptor, which mediates lysosomal enzyme uptake. 28 Another possibility is that, when it comes to secretion and uptake, there is an intrinsic difference between mouse GUS (used in our studies) and human GUS (used for other studies). 7, [11] [12] [13] The studies of Zhen et al 29 suggest that differences in the COOH terminal amino acids between the mouse and human GUS propeptides cause differences in extra-lysosomal complex formation, which may in turn affect secretion.
Similar to the expression of bacterial ␤-galactosidase 21 and human factor IX 23 from AAV vectors, the expression of GUS develops slowly over a period of several weeks following intramuscular administration of vector (see Figure 1 ). Since the half-life of GUS is 1-4 days depending on the tissue, 7, 30 we conclude that GUS enzyme derived from AAV-GUS is not simply accumulating at a fixed rate, but that it is being produced at an increasing rate. This might suggest that the amount of vector DNA sequence should also be increasing over the time-course examined. However, our results demonstrate that the amount of vector remaining inside the muscle is not proportional to the amount of GUS enzyme being made. For this experiment the original dose was 3.4 × 10 11 vector particles per hind limb, which constituted an average dose of 7 × 10 3 per diploid nucleus assuming 5 × 10 7 nuclei per hind limb. In reasonable agreement with this estimated dose, the measured relative concentration of vector DNA 1 day after injection was 8.5 ng/g total DNA, which is equivalent to 1.1 × 10 4 copies of the vector per diploid genome (using 4.7 × 10 3 bp as the vector size and 3 × 10 9 bp as the haploid mouse genome size). With time the amount of vector DNA sequence dropped dramatically and appeared to stabilize by 6 weeks at about eight copies per nucleus. Thus, the vast majority of the vector sequence is unstable and does not persist for extended times. It should be noted that the number of vector copies per nucleus is an average for the entire leg. In reality, we expect the vector to be unevenly distributed with higher concentrations at the actual sites of injection. 20 These results suggest that only a small fraction of the administered DNA is responsible for all of the GUS activity. Furthermore, this DNA appears to be progressively activated over an extended period of time. The nature of stabilization and activation of vector DNA is not known, although the synthesis of second-strand DNA is presumably involved. 31 In general, AAV vectors from which the rep gene is deleted are considered defective in their ability to integrate into the host genome, but low frequency, random integration has been demonstrated. 32, 33 In the case of AAV-GUS, it is not clear whether the small fraction of surviving vector is integrated or persists as a stable episome.
Production of GUS enzyme from AAV-GUS in any given tissue depends on both delivery of the vector and its subsequent expression. For example, the paucity of GUS activity in the brains of treated MPS animals probably stems from inadequate delivery of vector to this organ. In contrast, livers of animals injected intravenously with 10 12 particles contained about 15 copies of vector per diploid nucleus after 13 weeks. This was slightly higher than the average vector concentration in injected muscle as discussed above, but the amount of GUS activity in liver was much lower. The mechanism behind the higher efficiency of AAV-GUS expression in muscle is not clear, but may be a function of both the promoter used to drive transcription and properties intrinsic to recombinant AAV vectors in general. Using an adenovirus vector to deliver the GUS coding sequence, Ohashi et al 16 found a different tissue distribution of GUS activity with spleen being relatively high. We have not yet characterized alternative promoters in this experimental system.
Production of GUS from AAV-GUS vector did not appear to elicit an immune response to the therapeutic protein. This suggested that the low levels of pre-existing GUS in MPS mice are sufficient to elicit immunotolerance or recognition as 'self' during development of the immune system. It is not known if an immune response to therapeutic GUS would occur in an individual absolutely null for GUS protein. It is clear that the encapsidated vector stimulates an immune response, presumably against the capsid proteins, although we have not tested this directly. This makes repeated administration of vector problematic.
Administration of AAV-GUS can reduce GAG levels and almost completely eliminate storage granules, at least in the liver. Although this may provide a substantial improvement in overall health, it is not sufficient. Storage in all tissues, particularly the brain, must be corrected. At least two possibilities for improvement exist. First, it may be possible to increase the number of cells and different cell types that take up and stabilize the vector. We have already shown that dose and route of administration have dramatic effects in this regard. Second, it may be possible to increase the redistribution of therapeutic enzyme by altering secretion and/or uptake. Then, high-producing cells could supply non-producing cells with the protein needed.
For the experiments presented only late juvenile and adult animals were used. Thus, although gene therapy might provide a dramatic improvement in overall health, irreversible damage (eg abnormal skeletal development and mental retardation) already has occurred. Ideally, therapy should start as soon as the disease is diagnosed. Experiments treating MPS mice shortly after birth are underway. Although Sly syndrome is rare in humans, many related storage diseases and other metabolic deficiencies are much more common. Hopefully, it will be possible to extend our results using an AAV vector to a number of these genetic disorders.
Materials and methods

Animals
Gus mps/+ mice in the original C57BL/6 (B6) background were obtained from E Birkenmeier (Jackson Laboratory, Bar Harbor, ME, USA) and were crossed to the congenic strain B6.Gus a . 34 From the progeny, Gus mps/a mice were selected and were used to establish a breeding colony in which both parents were always Gus mps/a and progeny carried mps/a, a/a or mps/mps allele combinations. The introduction of the a allele was done to aid genotyping by PCR. The homozygous, mps/mps mice generated were essentially identical to the original mutants. Presumably because of reduced viability, homozygous mutant (MPS) mice account for about 15-20% of the mice produced, which is somewhat less than the Mendelian expectation.
The am allele of Gus carries an induced mutation identified and provided by V Chapman (Roswell Park Cancer Institute, Buffalo, NY, USA). Because they show no genetic disease symptoms, these NN mice were bred as homozygotes. All procedures using mice were first reviewed and approved by an Institutional Animal Care and Use Committee and adhered to the principles of the NIH 'Guide for the Care and Use of Laboratory Animals.'
AAV vector
Vector construction, production and purification were analogous to those in previous reports. 20, 32, 35 AAV-GUS was made by inserting a mouse GUS cDNA sequence into the XhoI site of pV4.1, a plasmid containing a CMV promoter and flanking ITRs. The mouse DNA included 82 bp of genomic DNA 5′ to the GUS transcriptional start site, a full-length cDNA coding for the Gus-s a structural allele, and a piece of polylinker DNA including an XhoI site at the 3′ end. AAV-GUS particles were produced in an adenovirus-free system by cotransfecting 293 cells with vector DNA, with a plasmid containing the AAV rep and cap genes, and with a plasmid containing adenovirus helper genes. 35 Encapsidated DNA was purified by cesium chloride gradient centrifugation. Particle titers of greater than 10 13 per milliliter were achieved based on dot blot hybridization. It should be noted that the viable or infective titer may be significantly less than this physical titer.
Administration of vector AAV-GUS particles were suspended in sterile saline. For intramuscular injections one or both hind limbs were injected at two distinct sites per limb using 30 l per injection. Intravenous injections were 200 l via the tail vein.
Enzyme assay Fresh or frozen tissue was homogenized in 0.02 m imidazole (pH 7.4), 0.1% Triton X-100, and assayed for GUS enzyme activity by a fluorometric procedure using 4-methylumbelliferyl-␤-glucuronide as the substrate. 36 One unit is the amount of enzyme forming 1 mol of product per hour at 37°C. Specific activity is given as units per gram (wet weight) of tissue, or units per milligram protein for cultured cells. For per cent normal activity, the activity in a given tissue of a treated animal was compared with the same tissue in normal (Gus + /Gus + ) animals as shown in Table 1 .
Quantitative PCR of AAV vector DNA Tissue samples for DNA purification were homogenized, digested with proteinase K, and DNA was purified by phenol-chloroform extraction. 37 Template concentration standards consisted of purified plasmid DNA containing the AAV-GUS vector diluted in genomic DNA. DNA concentrations were determined by fluorescent staining using Hoechst 33258. 38 For the PCR data shown, primers that amplify a section of the vector DNA, but do not amplify any sequences in mouse genomic DNA were used (forward primer, 5′-TCCATAGAAGACACCGG GAC-3′; reverse primer, 5′-AATCCAGCCTTAT CCCAACC-3′; 412 bp PCR product). To confirm results, we used an alternate set of primers, one in exon 4 (forward primer, 5′-TGTCCAGGACACAAGCTTTG-3′) and one in exon 5 (reverse primer, 5′-ATGCTCATGCAT-CAGGTAAGG-3′). These amplified both AAV-GUS DNA (289 bp fragment from the cDNA sequence) and genomic GUS DNA (899 bp fragment including intron 4). Thus, the genomic sequence provided an internal control. Both sets of primers gave comparable results. For PCR reactions, 10 and/or 100 ng samples of DNA from AAV-GUStreated mice were used. Standards and samples were amplified for 30 cycles at an annealing temperature of 60°C. PCR products were separated electrophoretically on 2% agarose gels and stained with ethidium bromide. The integrated density values (IDV) of the bands were then calculated using an Alpha Imager (Alpha Innotech, San Leandro, CA, USA), which digitizes a video input and analyzes the information using computer software. Each set of PCR reactions using DNAs from treated mice was compared with a set of standards run and analyzed simultaneously. A representative standard curve ( Figure 3) shows that under the PCR conditions used, the amount of amplified product was strictly dependent on the amount of vector DNA present. The sensitivity was Ͻ0.2 pg of vector DNA in a background of 100 ng of mouse genomic DNA.
GAG determinations
We further modified the method developed by Farndale et al 39 and modified by Poorthuis et al. 10 About 50 mg of tissue was homogenized in 0.5 ml of buffer (50 mm TrisHCl, pH 7.5, 10 mm MgCl 2 , 2 mm Ca 2 Cl), digested with proteinase K for 4 h at 55°C, boiled for 15 min and treated with DNase I (20 U/ml) for 1 h at 37°C. After chloroform extraction, 100 l of the aqueous phase was passed through a 250 l Sephadex G-25 spin column. This removed contaminating small molecules that interfere with the dye-binding assay. The flow-through from the spin column was added to 900 l of dimethylmethylene blue reagent 39 and the absorbancy at 535 nm was measured. Experimental values were compared with chondroitin sulfate C (shark) standards. Protein concentration in the original homogenate was determined using Bio-Rad protein assay mix (Bio-Rad Laboratories, Hercules, CA, USA), and GAG content was expressed as microgram per milligram protein.
Histopathology
Mice were killed by cervical dislocation and immediately perfused via the left ventricle, first with saline and then with 10% neutral buffered formalin. The fixed animals with exposed viscera were then immersed in formalin before histopathologic evaluation. Selected tissues were routinely processed, embedded in paraffin, cut at approximately 5 microns, stained with hematoxylin and eosin, and examined microscopically.
